Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution

Wang Fangzheng, Jiang Chuner, Ye Zhiming, Liu Tongxin, Yan Fengqin, Wang Lei, Li Bin, Hu Fujun, Chen Ming, Qin Weifeng, Fu Zhenfu, Wang Fangzheng, Jiang Chuner, Ye Zhiming, Liu Tongxin, Yan Fengqin, Wang Lei, Li Bin, Hu Fujun, Chen Ming, Qin Weifeng, Fu Zhenfu

Abstract

In this retrospective review of a single institution's experience, the efficacy and safety of the long-term use of nimotuzumab in combination with intensity-modulated radiotherapy (IMRT) and chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC) were studied. Between August 2008 and March 2014, 39 newly diagnosed patients with stages III-IV NPC were treated with IMRT, chemotherapy, and nimotuzumab. Twenty patients were diagnosed with stage III (51.3%), 14 with stage IVA (35.9%), and 5 with stage IVB (12.8%) disease. All patients received at least one cycle of cisplatin-based induction chemotherapy followed by IMRT and more than nine cycles of nimotuzumab at 200 mg/week. Acute and late radiation-related toxicities were graded according to the Acute and Late Radiation Morbidity Scoring Criteria of the Radiation Therapy Oncology Group. Accumulated survival was calculated according to the Kaplan-Meier method. The log-rank test was used to compare survival differences. With a median follow-up of 46 months (range, 22-86 months), the estimated 3-year local recurrence-free, regional recurrence-free, distant metastasis-free, progression failure-free, and overall survival rates were 92.1%, 89.7%, 82.5%, 77.6%, and 86.8%, respectively. Univariate analysis showed that clinical stage and the cycle of induction chemotherapy were related with prognosis. The median cycle for the addition of nimotuzumab was 12 weeks. Grade 3 radiation-induced mucositis was observed in 15.8% of the treated patients. No skin rash or infusion reaction was observed, which is distinctly different from what was reported in patients treated with nimotuzumab. The major toxicities observed were grades I-II mucositis and leukocytopenia. Long-term use of nimotuzumab plus IMRT showed promising outcomes in terms of locoregional control and survival, without increasing the incidence of radiation-related toxicities in patients.

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Kaplan–Meier survival curves of local recurrence-free survival (LRFS), regional recurrence-free survival (RRFS), distant metastasis-free survival (DMFS), progression failure-free survival (PFS), and overall survival (OS).
Figure 2
Figure 2
Kaplan–Meier survival curves of LRFS for induction chemotherapy.
Figure 3
Figure 3
Kaplan–Meier survival curves of DMFS for clinical stage.

References

    1. Cao SM, Simons MJ, Qian CN. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin J Cancer 2011;30:114–19.
    1. Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:1765–77.
    1. Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma, a meta-analysis of the published literature. J Clin Oncol. 2004;22:4604–12.
    1. Baujat B, Audry H, Bourhis J, Chan AT, Onat H, Chua DT, Kwong DL, Al-Sarraf M, Chi KH, Hareyaa M, Leung SF, Thephamongkhol K, Pignon JP, MAC-NPC Collaborative Group. Chemotherapy in locally advanced nasopharyngeal carcinoma, an individual patient data meta-analysis of eight randomized trials and 1753 patients. Int J Radiat Oncol Biol Phys. 2006;64:47–56.
    1. Al-Sarraf M, LeBlanc M, Giri PG, Fu KK, Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE, Ensley JF. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099. J Clin Oncol. 1998;16:1310–7.
    1. Reddy BK, Lokesh V, Vidyasagar MS, Shenoy K, Babu KG, Shenoy A, Naveen T, Joseph B, Bonanthaya R, Nanjundappa, Bapsy PP, Loknatha, Shetty J, Prasad K, Tanvir Pasha CR. Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: A randomized, open-label, phase IIb, 5-year study in Indian patients. Oral Oncol. 2014;50:498–505.
    1. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy. Cancer 2002;94:1593–611.
    1. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59:11–20.
    1. Ma BB, Poon TC, To KF, Zee B, Mo FK, Chan CM, Ho S, Teo PM, Johnson PJ, Chan AT. Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma—A prospective study. Head Neck 2003;25:864–72.
    1. Leong JL, Loh KS, Putti TC, Goh BC, Tan LK. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004;114:153–7.
    1. Dorsey K and Agulnik M. Promising new molecular targeted therapies in head and neck cancer. Drugs 2013;73:315–25.
    1. Kohler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: A review. Onkologie 2013;36:510–8.
    1. Prenen H, Vecchione L, Van Cutsem E. Role of targeted agents in metastatic colorectal cancer. Targeted Oncol. 2013;8:83–96.
    1. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials 2013;34:8690–707.
    1. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssouflan H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-Year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11:21–8.
    1. Feng HX, Guo SP, Li GR, Zhong WH, Chen L, Huang LR, Qin HY. Toxicity of concurrent chemoradiotherapy with cetuximab for locoregionally advanced nasopharyngeal carcinoma. Med Oncol. 2014;31:170.
    1. Ma BB, Kam MK, Leung SF, Hui EP, King AD, Chan SL, Mo F, Loong H, Yu BK, Ahuja A, Chan AT. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol. 2012;23:1287–92.
    1. He X, Xu J, Guo W, Jiang X, Wang X, Zong D. Cetuximab in combination with chemoradiation after induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma: Preliminary results. Future Oncol. 2013;9:1459–67.
    1. Talavera A, Friemann R, Gomez-Puerta S, Martinez-Fleites C, Garrido G, Rabasa A, Lopez-Requena A, Pupo A, Johansen RF, Sanchez O, Krengel U, Morena E. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69:5851–9.
    1. Crombet T, Osorio M, Cruz T, Roca C, del Castillo R, Mon R, Iznaga-Escobar N, Figueredo R, Koropatnick J, Renginfor E, Fernandez E, Alvarez D, Torres O, Ramos M, Leonard I, Perez R, Lage A. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22:1646–54.
    1. Crombet T, Torres L, Neninger E, Catala M, Solano ME, Perera A, Torres O, Iznaga N, Torres F, Perez R, Lage A. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003;26:139–48.
    1. Du F, Zheng Z, Shi S, Jiang Z, Qu T, Yuan X, Sun Y, Song Y, Yang L, Zhao J, Wang J, Chi Y. S-1 and cisplatin with or without nimotuzumab for patients with untreated unresectable or metastatic gastric cancer: A randomized, open-label phase 2 trial. Medicine (Baltimore) 2015;94:e958.
    1. Huang XD, Xu GZ, Gao L, Xu GZ, Jin J, Yang WZ, Lu TX, Wu SX, Wu RR, Hu WH, Xie WC, Han F, Gao YH, Gao JM, Pan JJ, Chen CB, Lang JY, Li T, Dong L, Fu YB, Fan L, Li BS, Ni J, Wang XB, Chen BX, Gao XS, Zhang P, Wu XW, Hu BQ. A phase II study of (clinical study of) anti-epidermal growth factor receptor monoclonal antibody h-R3 combined with radiotherapy in the treatment of advanced nasopharyngeal carcinoma. Chin J Oncol. 2007;29:197–201.
    1. Rodriguez MO, Rivero TC, Del CBR, Muchuli CR, Bilbao MA, Vinageras EN, Alert J, Galainena JJ, Rodrigurez E, Gracias E, Mulen B, Wilkinson B, de Armas EL, Perez K, Pineda I, Frometa M, Leonard I, Mullens V, Viada C, Luaces P, Torres O, Iznaga N, Crombet T. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther. 2010;9:343–9.
    1. Liu ZG, Zhao Y, Tang J, Zhou YJ, Yang WJ, Qiu YF, Wang H. Nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma: A retrospective analysis. Oncotarget 2016;7:24429–35.
    1. Zhai RP, Ying HM, Kong FF, Du CR, Huang S, Zhou JJ, Hu CS. Experience with combination of nimotuzumab and intensity-modulated radiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Onco Targets Ther. 2015;8:3383–90.
    1. Cabanas R, Saurez G, Alert J, Reyes A, Valdes J, Gonzalez MC, Pedrayes JL, Valle L, Infante M, Avila M, Herrera R, Hechavarria E, Rios M, Femandez A, Lorenzo Luaces P, Crombet Ramos T. Prolonged use of nimotuzumab in children with central nervous system tumors: Safety and feasibility. Cancer Biother Radiopharm. 2014;29:173–8.
    1. Shanmugaratnam K and Sobin LH. The World Health Organization histological classification of tumors of the upper respiratory tract and ear. A commentary on the second edition. Cancer 1993;71:2689–97.
    1. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy. Bethesda (MD): ICRU;1993.
    1. International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon beam therapy (supplement to ICRU report 50). Bethesda (MD): ICRU;1999.
    1. Kwong DL, Sham JS, Leung LH, Cheng AC, Ng WM, Kwong PW, Lui WM, Yau CC, Wu PM, Wei W, Au G. Preliminary results of radiation dose escalation for locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2006;64:374–81.
    1. Ng WT, Lee MC, Hung WM, Choi CW, Lee KC, Chan OS, Lee AW. Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2011;79:420–8.
    1. Niu X, Hu C, Kong L. Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2013;139:1063–71.
    1. Zeng Q, Wang J, Lv X, Li J, Yin LJ, Xiang YQ, Guo X. Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in elderly patients with nasopharyngeal carcinoma: Finding from a propensity-matched analysis. BMC Cancer 2016;16:693–703.
    1. Lv X, Xia WX, Ke LR, Yang J, Qiu WZ, Yu YH, Liang H, Huang XJ, Liu GY, Zeng Q, Guo X, Xiang YQ. Comparison of the short-term efficacy between docetaxel plus carboplatin and 5-fluorouracil plus carboplatin in locoregionally advanced nasopharyngeal carcinoma. Onco Targets Ther. 2016;9:5123–31.
    1. OuYang PY, Bi ZF, Zhang LN, You KY, Xiao Y, Lan XW, Tang J, Wang XC, Deng W, Xie FY. Outcomes of induction chemotherapy plus intensity-modulated radiotherapy (IMRT) versus IMRT plus concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma: A propensity matched study. Transl Oncol. 2016;9:329–35.
    1. Sun Y, Li WF, Chen NY, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016;17(11):1509–20.
    1. Ramakrishnan MS, Eswaraiah A, Crombet T, Piedra P, Saurez G, Iyer H, Arvind AS. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs 2009;1:41–8.
    1. Hua YH, Ma SL, Fu ZF, Hu QY, Du LB, Jiang H. Effect of nimotuzumab on the radiation sensitivity of nasopharyngeal carcinoma cell line CNE-2. Chin J Zhejiang Med. 2011;33:836–9.
    1. Wang FZ, Sun QQ, Jiang CE, Wang L, Yan FQ, Ye ZM, Liu TX, Xu M, Wu P, Jiang HT, Rihito A, Masoto S, Wang YZ, Fu ZF. Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma. Oncotarget. 2017;8:96798–808.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit